Advertisement
Organisation › Details
IP Group (Group)
IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiary IP Capital), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in approximately 80 early-stage to mature businesses across four main sectors -- Biotech, Cleantech, Healthcare and Technology. The Company is listed on the Main Market of the London Stock Exchange under the code IPO. *
Start | 2006-04-26 renamed | |
Predecessor | IP2IPO (Group) | |
Industry | IP services | |
Industry 2 | venture capital | |
Person | Smith, Greg (IP Group 2022 CEO before CFO) | |
Person 2 | Baynes, David (IP Group 202112 CFO formerly Fusion IP + Biofusion) | |
Region | London, Greater London | |
Country | United Kingdom (GB) | |
Street | 24 Cornhill | |
City | EC3V 3ND London | |
Tel | +44-845-074-2929 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | C: 51 to 100 (2021-12-31) |
Currency | GBP | |
Annual sales | 508,900,000 (portfolio return + revenue, consolidated (2021) 2021-12-31) | |
Profit | 449,300,000 (2021-12-31) | |
Cash | 105,700,000 (2021-12-31) | |
* Document for »About Section«: | ||
Record changed: 2022-09-20 |
Advertisement
More documents for IP Group (Group)
- [1] PhoreMost Ltd.. (9/10/24). "Press Release: PhoreMost Extends Series B Financing to $50M to Advance High-value Oncology and Inflammation Degrader Programmes". Cambridge....
- [2] Elsamogen Ltd.. (5/18/22). "Press Release: BGF, Scottish National Investment Bank and Scottish Enterprise Join Forces to Invest £8m in Aberdeen Biologics Company Elasmogen". Aberdeen....
- [3] Semarion Ltd.. (2/22/22). "Press Release: Semarion Raises £2.14m Seed Funding to Commercialise Cell Assaying Platform". Cambridge....
- [4] Boehringer Ingelheim. (10/19/21). "Press Release: Boehringer Ingelheim and Partners to Accelerate Development of First-In-Class Gene Therapy for Patients with Cystic Fibrosis". Paris....
- [5] IP Group plc. (5/4/21). "Press Release: Portfolio Company Oxford Nanopore Technologies Raises £195m in New Investment"....
- [6] Mogrify Ltd.. (5/4/21). "Press Release: Mogrify Completes Series A financing Totaling $33 Million USD". Cambridge....
- [7] CytoSeek Ltd.. (3/16/21). "Press Release: CytoSeek Raises £3.57M ($5M) to Advance Its Mission to Develop the Next Generation of Cell Therapies for Cancer". Bristol....
- [8] PredictImmune Ltd.. (7/30/19). "Press Release: PredictImmune Closes Series B Funding Round, Raising £10M to Further Accelerate Global Commercial Expansion and Support Expanding Product Pipeline". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top